StockData
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. (AVR) company profile

AVRNasdaqOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$5.32−0.38 (-6.67%)

Close on Nov 17, 2026Market cap $518.48MP/E –Yield –

About Anteris Technologies Global

Orthopedic, Prosthetic & Surgical Appliances & Supplies, SIC 3842

Anteris Technologies Global Corp. is a structural heart company that develops medical devices to treat aortic stenosis. Its primary product candidate is the DurAVR Transcatheter Heart Valve System, a balloon-expandable transcatheter aortic valve replacement made with a single piece of bioengineered bovine pericardial tissue. The system incorporates the company's proprietary ADAPT anti-calcification tissue technology and is deployed using its ComASUR Delivery System. The technology serves patients suffering from aortic stenosis, including those undergoing initial valve replacement as well as valve-in-valve procedures.

The company operates internationally and conducts clinical trials across North America and Europe, including Denmark and the United States. Its tissue technology has been distributed for use in more than 55,000 patients globally, and over 130 patients have received implants of its transcatheter heart valve worldwide. Anteris Technologies Global Corp. maintains its principal executive offices in Toowong, Queensland, Australia.

Summary of the business section of Anteris Technologies Global's latest annual report, written by StockData.

Company profile

Company

Legal name
Anteris Technologies Global Corp.
Headquarters
Eagan, MN
Address
860 Blue Gentian Road, Suite 340 55121
Phone
(651) 493-0606
Employees
174, Dec 31, 2025
Industry
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG, Brisbane, Australia

Stock & identifiers

Ticker
AVR
Exchange
Nasdaq
IPO date
Dec 13, 2024
Shares outstanding
97M, Aug 10, 2026
Filer category
<br>Emerging growth company
SEC CIK
2011514
CUSIP
03675P102
ISIN
US03675P1021
FIGI
BBG01PLXJNR7
Share class FIGI
BBG01PLXJQ81
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Denis David StChief Operating Officer, Director161,082
Wayne PatersonChief Executive Officer, Director203,061
Eric SchwartzChief Legal Officer–
Brent MoenChief Financial Officer–
Matthew McDonnellChief Financial Officer50,183
David B. RobertsDirector17,580
Gregory S. MossDirector17,580
Susan Elizabeth KnightDirector11,000
Stephen DenaroDirector23,722
John D. SeabergDirector47,487
Wenyi GuDirector–

Executive compensation, fiscal 2024

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Wayne Paterson
Vice Chairman and Chief Executive Officer
$696.39K$125.00K–$1.46M$725.00K$35.53K$3.04M-55%
David St Denis
President and Former Chief Operating Officer
$450.00K$50.00K$3.00M–$380.00K$34.60K$3.91M-17%
Matthew McDonnell
Chief Financial Officer
$267.43K$50.00K$500.00K–$158.76K$24.47K$1.00M-39%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Dec 13, 2024
Offer price
$6.00
Securities offered
14,800,000
Gross proceeds
$88.80M
Exchange
Nasdaq
Lock-up ends (est.)
Jun 11, 2025

“We are offering 14,800,000 shares of our Common Stock to be sold in this offering at an initial public offering price of $6.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had approximately 174 full time equivalent employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?